Search

Displaying results 3391 - 3400 of 9333 in total
  1. Drug

    Lactitol

    go.drugbank.com/drugs/DB12942
    Approved

    [A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.[L11803] … [A190912] Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in

  2. Drug

    Methoxamine

    go.drugbank.com/drugs/DB00723
    ApprovedInvestigationalWithdrawn

    It has little if any direct effect on the central nervous system.

  3. Drug

    Tafamidis

    go.drugbank.com/drugs/DB11644
    ApprovedInvestigational

    [A189717] Tafamidis is structurally similar to diflusinal.[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]

  4. Drug

    Viper antivenom

    go.drugbank.com/drugs/DB14114
    ApprovedInvestigational

    ANAVIP, an equine-derived antivenom made with venom from _Bothrops asper_ and _Crotalus durissus_, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation

  5. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria.

  6. Drug

    Ioflupane I-123

    go.drugbank.com/drugs/DB08824
    ApprovedInvestigational

    Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes.

  7. Drug

    Chamaecyparis obtusa wood oil

    go.drugbank.com/drugs/DB14341
    Investigational

    Chamaecyparis obtusa wood oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: Ste-medi
  8. Drug

    Arimoclomol

    go.drugbank.com/drugs/DB05025
    Approved

    [L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC).

  9. Drug

    Lysergic acid diethylamide

    go.drugbank.com/drugs/DB04829
    IllicitInvestigational

    Some say HPPD is a manifestation of post-traumatic stress disorder, not related to the direct action of LSD on brain chemistry, and varies according to the susceptibility of the individual to the disorder … Many emotionally intense experiences can lead to flashbacks when a person is reminded acutely of the original experience.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Hexylcaine

    go.drugbank.com/drugs/DB00473
    ApprovedWithdrawn

    Hexylcaine has been discontinued in the US market. … Patients experience an overdose may present with headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function.